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Abstract
Candida albicans is an opportunistic pathogen accounting for the majority of cases of Candida infections. Currently, C. albicans 
are developing resistance towards different classes of antifungal drugs and this has become a global health burden that does 
not spare Lebanon. This study aims at determining point mutations in genes known to be involved in resistance acquisition and 
correlating resistance to virulence and ergosterol content in the azole resistant C. albicans isolate CA77 from Lebanon. This 
pilot study is the first of its kind to be implemented in Lebanon. We carried out whole genome sequencing of the azole resist-
ant C. albicans isolate CA77 and examined 18 genes involved in antifungal resistance. To correlate genotype to phenotype, we 
evaluated the virulence potential of this isolate by injecting it into BALB/c mice and we quantified membrane ergosterol. Whole 
genome sequencing revealed that eight out of 18 genes involved in antifungal resistance were mutated in previously reported 
and novel residues. These genotypic changes were associated with an increase in ergosterol content but no discrepancy in 
virulence potential was observed between our isolate and the susceptible C. albicans control strain SC5314. This suggests 
that antifungal resistance and virulence potential in this antifungal resistant isolate are not correlated and that resistance is a 
result of an increase in membrane ergosterol content and the occurrence of point mutations in genes involved in the ergosterol 
biosynthesis pathway.
DATA SUMMARY
The authors confirm that all protocols have been provided 
within the article and relevant supplementary material depos-
ited in GenBank. Deposition and accession numbers are also 
provided.
INTRODUCTION
Candida is a genus of fungi that is part of the normal human 
microbiota, colonizing many bodily parts such as the gut 
and skin [1]. In immunocompromised hosts, Candida is an 
opportunistic pathogen [2], leading to deadly disseminated 
systemic infections in its most severe form [3]. In hospital-
ized patients, the diploid Candida albicans species causes the 
majority of cases of Candida infections [1].
Generally, C. albicans infections are treated with topical or 
systemic antifungal drugs belonging to the following classes: 
allylamines, azoles, echinocandins, morpholines, and poly-
enes [4]. Allylamines, azoles, and morpholines interfere with 
genes that code for enzymes having crucial roles within the 
ergosterol biosynthesis pathway. This yeast metabolic pathway 
allows the conversion of acetyl coenzyme A into the lipid 
ergosterol which is the main component of the C. albicans cell 
membrane. Within the ergosterol biosynthesis pathway, ally-
lamines and azoles mainly target the ERG1 and ERG11 genes, 
respectively while morpholines mainly target the ERG24 and 
ERG2 genes [5, 6]. Regarding polyenes, they act by directly 
binding to ergosterol at the level of the C. albicans cell wall 
rendering it more permeable. Echinocandins, on the other 
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mainly inhibit the action of beta-1,3- D- glucan synthase [7]. In 
fact, resistance towards antifungal drugs relies on many mech-
anisms. The two main mechanisms involved are: (1) Altera-
tions at the level of target genes such as the genes that code 
for squalene epoxidase and lanosterol 14- alpha demethylase 
among others. This alteration in target genes is the outcome 
of an overexpression or point mutations. Overexpression of 
target genes allows to compensate for the inhibition of its 
protein product caused by the antifungal drug while point 
mutations lead to a reduced affinity of antifungal drugs to the 
target protein. (2) Changes in cell wall and plasma membrane 
permeability due to changes in their composition, an active 
efflux or a reduced import of antifungals. In addition to the 
two main mechanisms mentioned above; metabolic bypass, 
regulation of oxidative stress response, regulation of thermal 
stress, and metal deficiency could be at the basis of antifungal 
resistance mechanisms in C. albicans [8]. The development of 
resistance towards antifungals in C. albicans is on the rise as a 
result of an improper management and treatment of infections 
and the challenging task of discovering new antifungals since 
C. albicans have relatively high rates of gene orthology with 
humans [9, 10]. Consequently, C. albicans infections pose a 
serious public health threat worldwide including Lebanon. 
To date only a handful of studies have addressed resistance 
of Lebanese C. albicans isolates to azoles, echinocandins, and 
polyenes [11–17] but none of the studies have looked at the 
entire genome of C. albicans to generate a complete picture 
of the genomic aspects of antifungal resistance.
The aim of this pilot study was to perform whole genome 
sequencing of an antifungal resistant C. albicans clinical 
isolate from Lebanon in order to analyse a significant number 
of genes involved in antifungal resistance at once. We focused 
on 18 genes of which eight (ERG1, ERG11, ERG24, ERG251, 
ERG6, ERG2, ERG3, ERG5) code for crucial proteins within 
the ergosterol biosynthesis pathway [5, 6, 18], one (UPC2) 
codes for a regulator of many genes involved in the ergosterol 
biosynthesis pathway, three (CDR1, CDR2, and MDR1) code 
for efflux pumps, three (TAC1, MRR1, and MRR2) code for 
efflux pump regulators [8, 19], two (FKS1 and FKS2) code 
for different subunits of beta-1,3- D- glucan synthase which is 
involved in the assembly of the beta-1,3- glucan at the level of 
the cell wall (7), and one (GLS1) codes for alpha- glucosidase 
I which is implicated in the assembly of the beta-1,6- glucan 
cell wall component [20]. Most of these targets are considered 
to be cell surface proteins [21]. In parallel, the genotypic data 
generated for this resistant C. albicans isolate were correlated 
to the following phenotypic aspects: minimum inhibitory 
concentration (MIC) of some azoles (fluconazole, itracona-
zole, ketoconazole, and voriconazole), MIC of the echino-
candin caspofungin, MIC of the polyene amphotericin B, 
virulence potential, and membrane ergosterol content. Fig. 1 
summarizes the methodology and results of this pilot study.
METHODS
Case presentation
The C. albicans strain (designated as CA77) was isolated from 
a stool sample of a patient admitted in a tertiary care center 
in Beirut, Lebanon. The patient was suffering from diarrhea 
and did not have any history of antibiotic treatment before 
being admitted.
Fig. 1. Summary. The C. albicans resistant strain was whole genome sequenced, and membrane ergosterol levels determined. Increase 
in ergosterol content partially explains the increased drug resistance phenotypes observed. Point mutations in key resistance genes 
were also isolated.
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Antifungal resistance
Susceptibility to fluconazole (FL), itraconazole (IT), keto-
conazole (KE), voriconazole (VO), amphotericin B (AP), 
and caspofungin (CS) was evaluated for CA77 using the 
E- test (BioMérieux) method according to the manufacturer’s 
instructions. Candida parapsilosis ATCC 22019 and Candida 
albicans ATCC 90028 were used as quality control standards 
with our values falling within the CLSI approved range [22].
Virulence potential
CA77 was inoculated onto potato dextrose agar (Conda 
Laboratories, Madrid, Spain) and incubated for 48h at 30 °C. 
Then, 10 ml of potato dextrose broth (Conda Laboratories, 
Madrid, Spain) was inoculated with one colony of CA77 and 
incubated for 18h at 30 °C with shaking at 100 r.p.m. Then 
107 cells were harvested and suspended in 0.2 ml of a 1× 
phosphate- buffered saline solution and injected into the tail 
vein of 6- week- old female BALB/c mice in order to induce a 
disseminated systemic infection. Water and food were admin-
istered ad libitum. In total, six BALB/c mice were injected 
with CA77. The mice were monitored on a daily basis for a 
period of 1 month and the number of moribund mice was 
counted. Moribund mice were euthanized [15, 23–25]. The 
same protocol was carried out for the reference C. albicans 
SC5314 strain (ATCC MYA-2876) known to be susceptible 
to all antifungals.
Quantification of membrane ergosterol
CA77 was inoculated onto potato dextrose agar (Conda 
Laboratories, Madrid, Spain) and incubated for 48h at 30 °C. 
Then, 50 ml of potato dextrose broth (Conda Laboratories, 
Madrid, Spain) was inoculated with one colony of CA77 
and incubated for 17h at 35 °C with shaking at 100 r.p.m. 
The extraction and quantification of ergosterol from CA77 
followed the protocol described in [26]. Briefly, yeast cells 
were collected by centrifugation at 2700 r.p.m. for 5 min 
and washed once with sterile distilled water. The wet weight 
of the yeast pellet was measured. A saponification reaction 
was carried out by adding 3 ml of a 25% alcoholic potassium 
hydroxide solution to the weighed pellet of yeast cells. The 
suspension was vortexed for 1 min, transferred to a glass 
screw- cap tube, and incubated in a water bath for 1h at 85 °C. 
The tube was cooled down at room temperature for 15 min. 
The nonsaponifiable sterols were extracted by adding 1 ml 
of sterile distilled water and 3 ml of n- heptane. The mixture 
was vortexed for 3 min and incubated at room temperature 
for 1h to allow phase separation. The n- heptane layer was 
transferred to a clean glass screw- cap tube and incubated at 
-20 °C for 24h. A fivefold dilution of the n- heptane layer in 
100% ethanol was performed and optical density measure-
ments at 230 and 281.5 nm were taken using a Genesys 10S 
UV- Vis spectrophotometer. The equations in [26] were used 
to calculate the ergosterol content as a percentage of the wet 
weight of yeast cells. The same protocol was carried out for 
the reference C. albicans SC5314 strain (ATCC MYA-2876) 
that is known to be susceptible to all antifungals. The experi-
ment was performed in biological triplicates and the average 
percentage ergosterol content was calculated for each isolate. 
The percentage change in ergosterol in the CA77 strains in 
comparison to the SC5314 strain was calculated.
DNA extraction
Whole genome DNA was extracted using the NucleoSpin 
Microbial DNA kit (Macherey- Nagel, Duren, Germany). 
The obtained DNA was sheared using the Covaris g- TUBEs 
(Covaris, USA). Library preparation was performed on the 
sheared DNA in accordance with the manufacturer’s recom-
mendation for microbial multiplexing protocol (Pacific 
Biosciences, Menlo Park, CA, USA). No size selection was 
performed during the library preparation. The constructed 
library was sequenced using long- read sequencing technology 
on Sequel I (Pacific Biosciences, Menlo Park, CA, USA).
Whole genome sequence data analysis
Initial PacBio long reads were pre- assembled and error 
corrected using HGAP4 offered through SMRT Link v.6.0 [27]. 
Pre- assembled reads were then assembled using FALCON 
(falcon- kit v1.8.0) with configuration files optimized for the 
purposes of yeast genome assembly using default settings. 
Finally, haplotype phasing was extended via FALCON- Unzip 
v1.3.5 using default settings [28]. Assemblies and/or reads 
were mapped against C. albicans SC5314 (GenBank acces-
sion numbers: NC_032089- NC_032096) using blast and 
Bowtie 2 v2.3.4.2 [29, 30] to investigate the completeness of 
the assembly across the different chromosomes. Comparison 
of our sequence with that of the Candida Genome Database 
to detect single nucleotide polymorphisms was done using 
Mauve [31].
RESULTS
In this pilot study, one C. albicans clinical isolate referred to 
as CA77 was screened for its capacity to resist the common 
antifungal azole drugs FL, IT, KE, and VO, in addition to the 
polyene AP, and the echinocandin CS by relying on the E- test 
method. We observed that CA77 was resistant to all tested 
azole antifungals but was susceptible to AP and CS. The MICs 
for all tested drugs are listed in Table 1.
Whole genome sequencing partially phased assembly resulted 
in a genome size of 14 133 179 bp with a GC content of 33.67%. 
When aligned against the reference genome SC5314, 95.7% 
coverage query was observed. Around 38 000 single nucleotide 
Table 1. Susceptibility of the C. albicans clinical isolate CA77 to common 
antifungal drugs. Minimum inhibitory concentration (MICs) obtained via 
the E- test method for fluconazole (FL), itraconazole (IT), ketoconazole 
(KE), and voriconazole (VO) show that the CA77 isolate is resistant 
to those antifungal drugs while MICs for amphotericin B (AP) and 
caspofungin (CS) show that it is susceptible to those drugs
MICs (μg ml−1)
FL IT KE VO AP CS
>256 >32 >32 >32 0.125 0.25
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polymorphisms were detected throughout the genome of the 
CA77 isolate, accounting for 0.27% of its genome. Previous 
studies found that single nucleotide polymorphisms account 
for 0.4 to 0.8% of the genome compared to the reference 
C. albicans strain SC5314 [32]. To generate a complete picture 
of antifungal resistance mechanisms at play in CA77 from a 
genetic perspective, 18 genes involved in antifungal resist-
ance (ERG1, ERG11, ERG24, ERG251, ERG6, ERG2, ERG3, 
ERG5, UPC2, CDR1, CDR2, MDR1, TAC1, MRR1, MRR2, 
FKS1, FKS2, and GLS1) were investigated. Whole genome 
sequencing showed that the following eight genes harbored 
point mutations: ERG11, ERG24, ERG251, UPC2, CDR1, 
MRR2, FKS1, and GLS1. Some of these genes exhibited more 
than one point mutation and all mutations were homozygous 
with no heterozygosity observed. All mutations are listed in 
Table 2. In total, 19 point mutations were observed of which 
to our knowledge, only nine were previously reported but do 
not have any clear implication in antifungal resistance.
Since most of these mutations are at the level of genes involved 
in the ergosterol biosynthesis pathway, we then decided to 
determine whether an association exists between the muta-
tions and an increase in membrane ergosterol content. We 
observed a 27% increase in membrane ergosterol content 
compared to the control SC5314 strain and this change in 
membrane composition could likely lead to impermeability 
towards azoles. Table  3 shows the ergosterol content in 
percentages in both CA77 and SC5314 C. albicans strains. 
Regarding virulence potential, no difference was observed 
between our resistant CA77 isolate and the control reference 
strain SC5314 that is susceptible to all antifungals since 
in both cases four out of six BALB/c mice were moribund 
following a disseminated systemic infection.
DISCUSSION
Whole genome sequencing has been used intensively in 
sequencing microbes especially in prokaryotes where data 
analysis is straightforward. However, diploid organisms pose 
challenges especially in extracting heterozygous loci [33]. In 
this study, heterozygosity in 18 genes has been investigated. 
We conducted a whole genome sequencing approach using 
long- reads sequencing; the first of its kind in Lebanon, to 
achieve a better assembly covering longer segments of the 
chromosomes and to determine the molecular basis of drug 
resistance in a Lebanese hospital isolate. The isolate exhibited 
resistance to the most commonly used azoles such as FL, IT, 
KE, and VO. We observed point mutations in eight genes 
involved in antifungal resistance: ERG11, ERG24, ERG251, 
UPC2, CDR1, MRR2, FKS1, and GLS1. In total, 19 point 
mutations were detected, of which nine were known to be 
uninvolved in antifungal resistance and ten were novel. Muta-
tions in genes involved in the ergosterol biosynthetic pathway 
might change the 3D structure of the enzyme preventing 
azoles from binding, resulting in resistance. The novel muta-
tions were detected in ERG24, ERG251, FKS1, and GLS1. Our 
E- test results show that the CA77 isolate is resistant to FL, 
IT, KE, and VO that belong to the azole class even though all 
four genes experiencing novel mutations are not azole targets. 
Nonetheless, the development of resistance towards azoles 
could be explained by ergosterol content that shows a 27% 
increase compared to the reference strain SC5314. This leads 
to a change in the membrane composition of CA77 likely 
rendering it impermeable to azole antifungals that were no 
longer able to reach their target within the C. albicans cell. 
However, other studies did not detect an increase in ergos-
terol content in azole- resistant compared to azole- susceptible 
C. albicans isolated from humans and animals [34, 35]. In 
addition to azole resistance, we speculate that this strain might 
be resistant to morpholine antifungals that could have ERG24 
Table 2. A list of known and novel mutations detected by whole genome sequencing in genes involved in antifungal resistance in the C. albicans clinical 
isolate CA77
Genes Mutations Mutation description References
ERG11 D116E Known mutation but not previously involved in antifungal resistance [36]
ERG24 H46Q – I88V – A307V Novel mutations –
ERG251 R310Q Novel mutation –
UPC2 I142S Known mutation but not previously involved in antifungal resistance [36]
CDR1 T842S – T950S – E948P – I916V Known mutations but not previously involved in antifungal resistance [37]
MRR2 V451A – S480P Known mutations but not previously involved in antifungal resistance [38]
FKS1 P1838I Novel mutation –
T1886S Known mutation but not previously involved in antifungal resistance [36]
GLS1 T181I – I340V – Q459R – M679I – T938M Novel mutations –
Table 3. Ergosterol content in C. albicans clinical isolate CA77 and 
reference strain SC5314. The average ergosterol content of the three 
biological triplicates along with the standard deviation are listed in this 
table
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as target [5, 6]. The ERG251 gene is not a direct antifungal 
target [18] so, it is difficult to speculate about the implication 
of mutations at the level of this gene on antifungal resist-
ance. Mutations at the level of ERG24 and ERG251 are rarely 
observed. Moreover, FKS1 and GLS1 are genes that code for a 
subunit of beta-1,3- D- glucan synthase and alpha- glucosidase 
I involved in the assembly of the cell wall beta-1,3- glucan and 
beta-1,6- glucan, respectively. In general, point mutations at 
the level of those genes could reduce sensitivity to echinocan-
dins [7, 20]. However, we observed no correlation between 
antifungal resistance and the virulence potential of CA77 
in contrast to what has been observed in C. albicans clinical 
isolates from Lebanon that were resistant to CS. These isolates 
exhibited a lower virulence potential which was associated 
with an increased chitin deposition at the level of the cell 
wall rendering it thicker and thus, preventing filamentation 
which is crucial for the establishment of virulence. However, 
most ergosterol enzymes, as opposed to enzymes targeted 
by echinocandins, are not associated with the cell wall so 
such a correlation is not to be expected [15]. In light of an 
absence of change in virulence potential between CA77 and 
the reference strain SC5314 that is susceptible to all antifungal 
drugs we could postulate that the novel mutations harbored 
by FKS1 and GLS1 are probably not involved in resistance to 
echinocandins and definitely not implicated in resistance to 
the echinocandin CS according to our E- test results.
CONCLUSION
In conclusion, the C. albicans CA77 strain isolated from a 
hospitalized patient in Lebanon and which is resistant to 
the most commonly used azole antifungals was subjected 
to a whole genome sequencing analysis which revealed the 
occurrence of 19 point mutations in eight genes involved 
in antifungal resistance. Of these mutations, nine were 
previously documented and known to be uninvolved in 
the development of antifungal resistance and ten were 
novel mutations but not harbored by azole targets. This 
development of resistance towards azoles is thought to be 
the result of a change in membrane composition due to an 
increase in ergosterol content (Fig. 1). Finally, our whole 
genome sequencing pilot study is the first of its kind to be 
carried out in Lebanon and will pave the way to a large- 
scale project to elucidate mechanisms of drug resistance 
in Candida fungi.
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